Table 2 Lesion characteristics of patients treated with zotarolimus-eluting (ZES) or sirolimus-eluting (SES) stents

Vessel

<0.0001

  LM

99 (3.2%)

158 (3.1%)

  LAD

1,255 (41%)

2,388 (47%)

  LCX

743 (24%)

1,154 (23%)

  RCA

991 (32%)

1394 (27%)

Sapheneous vein graft

36 (0.9%)

44 (1.2%)

0.18

Restenotic lesion

87 (2.8%)

74 (1.5%)

<0.0001

Stent thrombosis lesion

28 (0.9%)

24 (0.5%)

0.0076

Lesion length*

12 (10-20) mm

15 (10-20) mm

0.027

Lesion type

0.0008

  A

659 (21%)

1,100 (22%)

  B1

823 (27%)

1,542 (30%)

  B2

629 (20%)

1,014 (20%)

  C

979 (32%)

1,439 (28%)

Stent length^†

19.9 ± 11.9 mm

20.2 ± 11.9 mm

<0.0001

Number of stents >1

581 (18.8%)

837 (16.4%)

0.006